Epigenetics Drugs Diagnostic Technologies Companies

Illumina (US) Launched the CE IVD marked Next Generation Sequencing Instrument in March 2022, enabling both diagnostic testing and clinical research on a single platform.

PacBio (US) Acquired Apton Biosystems (US) in August 2023 to accelerate the development of a high-throughput, short-read sequencer for epigenetic research.

Epizyme (US) Received FDA Breakthrough Therapy Designation for EZH2 inhibitor tazemetostat in combination with chemotherapy for metastatic triple-negative breast cancer in December 2023.

Celleon Therapeutics (US) Initiated Phase 1/2 clinical trial in October 2023 for TLX250, a first-in-class histone methyltransferase inhibitor for the treatment of advanced solid tumors.

Twentyeight-seven Therapeutics (US) Announced positive interim data from Phase 1b/2 clinical trial for EPZ-6438, a DOT1L inhibitor for the treatment of acute myeloid leukemia (AML) in November 2023.

List of Epigenetics Drugs Diagnostic Technologies Key Companies in the Market

• Hologic, Inc. (US)


• Gilead Sciences, Inc. (US)


• Celleron Therapeutics (US)


• Illumina, Inc. (US)


• AstraZeneca PLC (UK)


• LISEN lmprinting Diagnostics (US)


• Salarius Pharmaceuticals, Inc. (US)


• Jubilant Therapeutics (US)


• Oryzon Genomics (Spain)


• Epiaxis Therapeutics (Australia)